The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 12, 2024
Filed:
Nov. 10, 2023
Bayer Aktiengesellschaft, Leverkusen, DE;
Bayer Pharma Aktiengesellschaft, Berlin, DE;
Eva Maria Becker-Pelster, Wuppertal, DE;
Hanna Tinel, Wuppertal, DE;
Michael Hahn, Langenfeld, DE;
Dieter Lang, Velbert, DE;
Gerrit Weimann, Bergisch-Gladbach, DE;
Johannes Nagelschmitz, Wuppertal, DE;
Lisa Dietz, Wuppertal, DE;
Soundos Saleh, Wuppertal, DE;
David Jung, Wittenberg, DE;
Ildiko Terebesi, Berlin, DE;
Tobias Mundry, Berlin, DE;
Annett Richter, Berlin, DE;
Britta Olenik, Bottrop, DE;
Birgit Keil, Dusseldorf, DE;
Bernd Rösler, Wuppertal, DE;
Peter Fey, Wuppertal, DE;
Heiko Schirmer, Solingen, DE;
Guido Becker, Krefeld, DE;
Clemens Bothe, Leverkusen, DE;
Helene Faber, Dormagen, DE;
Julian Egger, Remscheid, DE;
Mark Parry, Essex, GB;
David Ward, Cambridgeshire, GB;
Cecile Vitre, Cambridgeshire, GB;
Bayer Aktiengesellschaft, Leverkusen, DE;
Bayer Pharma Aktiengesellschaft, Berlin, DE;
Abstract
The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension with idiopathic interstitial pneumonia (PH-IIP), characterized in that an inhalative dosage form comprising 240 to 4000 μg, preferably 480 to 2000 μg of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxy lie acid of formula (I), preferably in form of one of its salts or solvates or hydrates, preferably in form of monohydrate I of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxy lie acid in form of mono hydrate (II) of formula (I-M-II), is administered to a patient in need thereof once or twice daily for a period of at least two consecutive days, preferably at least 2 to 7 consecutive days, preferably for a period of at least 14 consecutive days, in particular from after onset of treatment for the whole course of the disease, wherein the inhalative dosage form preferably comprises the combination of the active ingredient and a pharmaceutically suitable excipient or carrier, while preferably the active ingredient and a pharmaceutically suitable excipient are filled in a hard capsule.